Whole exome sequencing on paired baseline and progressing lesions of melanoma patients having initially responded to anti-PD-1 therapy, identified the loss of function mutations in JAK1 and JAK2 genes, which are involved in the IFN-γ signaling pathway, as mechanisms of acquired resistance to PD-1 inhibitors [201]. The gene discussed is PDCD1; the disease is melanoma.